BioNtech SE：2021年Q1营收20.48亿欧元，市场预期14.78亿欧元，去年同期0.28亿欧元。
2021年Q1净利润（亿欧元）：11.28 ，预期：9.32，前值：-0.53。
2021年Q1每股盈利4.39欧元，市场预期盈利3.09欧元，去年同期亏损0.24欧元。
2021年公司已经签署了超过1.8亿剂BNT162B2疫苗的协议，并签署了2022年及以后阶段的首批合同。目前全年疫苗产能目标是30亿剂，2022年将超过30亿剂。
预计于近期签订合同的新冠疫苗完成交付后的带来的收益约为124亿欧元。维持2021年财务展望不变。
公布财报后，BioNTech SE盘前一度拉升至近11%，现涨幅收窄至8%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments